ABBV Stock Price Today (October 2026) — AbbVie Inc. Analysis & Key Metrics 2026-10-21
AbbVie Inc. (ABBV) is trading at $289.08, up 2.26% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $282.61 (2.2% downside).
- Volatility is low (20.47% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
ABBV Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $575.15B
P/E Ratio
Forward P/E: 15.75
Revenue Growth
Year over Year
Analyst Target
-2.2% downside from target
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 65.15)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $70.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $190.75 and $291.33 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.47% annualized volatility and β=0.04, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
2 High-Flying Dividend Stocks to Buy and Hold for a Decade
How Much Upside Is Left In Regeneron Stock?
What Has Changed About Owning Gilead Stock?
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?
Has Johnson & Johnson Stock Become A Different Bet?
Latest TickZen Insights
All insights →No TickZen article on ABBV yet. Our newest analysis:
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 30, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $289.08. The RSI (14-day) is at 65.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $282.61 implies 2.2% downside from current levels. Volatility is moderate at 20.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 73.74, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.42, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Sales is 7.18. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering ABBV, the consensus price target is $282.61. This represents a 2.2% downside from the current price of $289.08. The range spans from a low target of $200.00 to a high target of $328.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 2.52%. The annualized dividend rate is $6.83 per share. The payout ratio is 190.4%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was Oct 15, 2026.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (190%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $70.88B. The current ratio is 0.81, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.49. The company holds $6.57B in cash and equivalents. Free cash flow is positive at $16.87B, providing a cushion for debt servicing and shareholder returns.